clindamycin has been researched along with nadifloxacin in 5 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (20.00) | 18.2507 |
| 2000's | 3 (60.00) | 29.6817 |
| 2010's | 1 (20.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Komagata, Y; Komiyama, K; Nomura, S | 1 |
| Hayashi, K; Mitsuyama, J; Yamakawa, T | 1 |
| Kikuchi, M; Kitagaki, H; Kitazawa, T; Kuwahara, K; Tsukamoto, T | 1 |
| Murata, K; Tokura, Y | 1 |
| Ito, A; Noguchi, N; Sasatsu, M; Sato, T; Shirane, T | 1 |
1 review(s) available for clindamycin and nadifloxacin
| Article | Year |
|---|---|
[Anti-microbial therapies for acne vulgaris: anti-inflammatory actions of anti-microbial drugs and their effectiveness].
Topics: Acne Vulgaris; Administration, Topical; Anti-Bacterial Agents; Anti-Inflammatory Agents; Clindamycin; Fluoroquinolones; Humans; Immunologic Factors; Macrolides; Propionibacterium acnes; Quinolizines; Tetracycline | 2007 |
4 other study(ies) available for clindamycin and nadifloxacin
| Article | Year |
|---|---|
[Fundamental studies on antibacterial activity of clindamycin against Propionibacterium acnes].
Topics: Administration, Topical; Animals; Anti-Bacterial Agents; Anti-Infective Agents; Clindamycin; Dose-Response Relationship, Drug; Drug Resistance, Microbial; Fluoroquinolones; Gram-Positive Bacterial Infections; Male; Mice; Mice, Inbred Strains; Propionibacterium acnes; Quinolizines; Skin Diseases, Bacterial | 1998 |
In vitro and in vivo antibacterial activity of T-3912, a novel non-fluorinated topical quinolone.
Topics: Animals; Anti-Infective Agents; Clindamycin; Colony Count, Microbial; DNA Topoisomerase IV; Drug Resistance, Bacterial; Erythromycin; Fluoroquinolones; Gene Frequency; Genes, Bacterial; Gentamicins; Levofloxacin; Male; Mice; Mice, Inbred ICR; Microbial Sensitivity Tests; Mutation; Ofloxacin; Quinolines; Quinolizines; Staphylococcal Skin Infections; Staphylococcus aureus; Staphylococcus epidermidis; Topoisomerase II Inhibitors | 2002 |
Nadifloxacin, an antiacne quinolone antimicrobial, inhibits the production of proinflammatory cytokines by human peripheral blood mononuclear cells and normal human keratinocytes.
Topics: Acne Vulgaris; Administration, Topical; Anti-Bacterial Agents; Cells, Cultured; Clindamycin; Corynebacterium; Cytokines; Dermatologic Agents; Drug Combinations; Enzyme-Linked Immunosorbent Assay; Fluoroquinolones; Humans; Inflammation Mediators; Interferon-gamma; Interleukin-1; Keratinocytes; Monocytes; Propionibacterium acnes; Quinolizines; Skin; Staphylococcus epidermidis; Up-Regulation | 2005 |
Novel anti-acne actions of nadifloxacin and clindamycin that inhibit the production of sebum, prostaglandin E(2) and promatrix metalloproteinase-2 in hamster sebocytes.
Topics: Acne Vulgaris; Animals; Anti-Inflammatory Agents, Non-Steroidal; Carrier Proteins; Cells, Cultured; Clindamycin; Cricetinae; Diacylglycerol O-Acyltransferase; Dinoprostone; Enzyme Precursors; Fluoroquinolones; Gelatinases; Gene Expression; Humans; Lipogenesis; Peptidoglycan; Perilipin-1; Phosphoproteins; Quinolizines; Sebaceous Glands; Sebum | 2012 |